OR WAIT null SECS
A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.
At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its role in obstructive hypertrophic cardiomyopathy (HCM).
Pushing it onto centerstage was a pair of studies detailing the long-term effects of use, a single study demonstrating the benefit among patients in China, and a new guideline update from the ESC focused on cardiomyopathies, which included Class IIa recommendations for mavacamten.
“The new long-term data presented at ESC were consistent with the primary analyses from each study, further underscoring the benefit our first-in-class therapy can provide to patients with symptomatic obstructive HCM,” said Amy Sehnert, MD Vice President, Head of Cardiomyopathy and Heart Failure Clinical Development, Bristol Myers Squibb.1 “These positive data reinforce the clinically meaningful significance of these two Phase 3 trials that led to the approval of CAMZYOS in the United States, the European Union and other countries around the globe. We are excited for the ongoing exploration of the potential of CAMZYOS and remain dedicated to providing support for obstructive HCM patients worldwide.”
“The presentation of data − the largest and longest analysis of patients on CAMZYOS to-date − illustrates the promise of this game-changing treatment for patients with symptomatic obstructive HCM,” said García-Pavia, who is the head of the Inherited Cardiac Diseases and Heart Failure Unit at the Department of Cardiology of Hospital Universitario Puerta de Hierro.1
During ESC Congress 2023, the ESC released the first international guidelines to include all cardiomyopathy subtypes. It is also marked the first time specific recommendations were made for cardiomyopathies other than HCM.4
Included in this new guideline were 2 recommendations for use of mavacamten:
For more on these studies, our editorial team sat down with Milind Desai, MD, MBA, principal investigator of VALOR-HCM, on-site at ESC Congress 2023. Check out the interview below for his perspective on the latest guideline update, the significance of including mavacamten in recommendations, and how ESC data complements our understanding of mavacamten in obstructive HCM.
Relevant disclosures for Desai include Bristol Myers Squibb, Cytokinetics, Tenaya, and others.